175 related articles for article (PubMed ID: 7504756)
1. [Palliative radiotherapy for bone pain in hormone refractory prostate cancer].
Kawakami S; Kawai T; Yamauchi T; Yonese J; Ueda T; Ishibashi K
Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1791-6. PubMed ID: 7504756
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy for the palliation of painful bone metastases.
McQuay HJ; Collins SL; Carroll D; Moore RA
Cochrane Database Syst Rev; 2000; (2):CD001793. PubMed ID: 10796822
[TBL] [Abstract][Full Text] [Related]
3. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
4. Palliative hemibody irradiation in hormonally refractory metastatic prostate cancer.
Nseyo UO; Fontanesi J; Naftulin BN
Urology; 1989 Aug; 34(2):76-9. PubMed ID: 2474883
[TBL] [Abstract][Full Text] [Related]
5. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
6. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate.
Paszkowski AL; Hewitt DJ; Taylor A
Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466
[TBL] [Abstract][Full Text] [Related]
7. [Palliative radiotherapy for local progression of hormone refractory stage D2 prostate cancer].
Kawakami S; Kawai T; Yonese J; Yamauchi T; Ishibashi K; Ueda T
Nihon Hinyokika Gakkai Zasshi; 1993 Sep; 84(9):1681-4. PubMed ID: 7692124
[TBL] [Abstract][Full Text] [Related]
8. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
[TBL] [Abstract][Full Text] [Related]
9. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases.
Sciuto R; Tofani A; Festa A; Giannarelli D; Pasqualoni R; Maini CL
J Nucl Med; 2000 Apr; 41(4):647-54. PubMed ID: 10768566
[TBL] [Abstract][Full Text] [Related]
11. External beam radiotherapy for palliation of pain from metastatic carcinoma of the prostate.
Benson RC; Hasan SM; Jones AG; Schlise S
J Urol; 1982 Jan; 127(1):69-71. PubMed ID: 6173495
[TBL] [Abstract][Full Text] [Related]
12. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens.
Zelefsky MJ; Scher HI; Forman JD; Linares LA; Curley T; Fuks Z
Int J Radiat Oncol Biol Phys; 1989 Dec; 17(6):1281-5. PubMed ID: 2480941
[TBL] [Abstract][Full Text] [Related]
13. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.
Crawford ED; Kozlowski JM; Debruyne FM; Fair WR; Logothetis CJ; Balmer C; Robinson RG; Porter AT; Kirk D
Urology; 1994 Oct; 44(4):481-5. PubMed ID: 7524233
[No Abstract] [Full Text] [Related]
14. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
15. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
16. [Radiosensitivity of bone metastases from tumors in different primary sites].
Khmelevsky EV; Bychkova NM
Vopr Onkol; 2015; 61(1):77-84. PubMed ID: 26016150
[TBL] [Abstract][Full Text] [Related]
17. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
18. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
19. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
Di Lorenzo G; Autorino R; Ciardiello F; Raben D; Bianco C; Troiani T; Pizza C; De Laurentiis M; Pensabene M; D'Armiento M; Bianco AR; De Placido S
Oncol Rep; 2003; 10(2):399-404. PubMed ID: 12579279
[TBL] [Abstract][Full Text] [Related]
20. [Palliative radiotherapy of bone metastases. A retrospective analysis of 176 patients].
Koswig S; Buchali A; Böhmer D; Schlenger L; Budach V
Strahlenther Onkol; 1999 Oct; 175(10):509-14. PubMed ID: 10554646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
